TWI845843B - 新型吡嗪化合物 - Google Patents
新型吡嗪化合物 Download PDFInfo
- Publication number
- TWI845843B TWI845843B TW110119810A TW110119810A TWI845843B TW I845843 B TWI845843 B TW I845843B TW 110119810 A TW110119810 A TW 110119810A TW 110119810 A TW110119810 A TW 110119810A TW I845843 B TWI845843 B TW I845843B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- mmol
- heterocycloalkyl
- pharmaceutically acceptable
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010486394.1 | 2020-06-01 | ||
| CN202010486394 | 2020-06-01 | ||
| CN202010947590 | 2020-09-10 | ||
| CN202010947590.4 | 2020-09-10 | ||
| CN202110587528.3 | 2021-05-27 | ||
| CN202110587528 | 2021-05-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202146406A TW202146406A (zh) | 2021-12-16 |
| TWI845843B true TWI845843B (zh) | 2024-06-21 |
Family
ID=78830119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110119810A TWI845843B (zh) | 2020-06-01 | 2021-06-01 | 新型吡嗪化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12600714B2 (enExample) |
| EP (1) | EP4159731A4 (enExample) |
| JP (1) | JP7777544B2 (enExample) |
| KR (1) | KR20230019444A (enExample) |
| CN (1) | CN115698000B (enExample) |
| AU (1) | AU2021284676A1 (enExample) |
| BR (1) | BR112022022220A2 (enExample) |
| CA (1) | CA3179395A1 (enExample) |
| MX (1) | MX2022013397A (enExample) |
| TW (1) | TWI845843B (enExample) |
| WO (1) | WO2021244505A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4373817B1 (en) * | 2021-07-20 | 2025-05-21 | Astrazeneca AB | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| WO2003045924A1 (en) * | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| JP5364159B2 (ja) * | 2009-05-08 | 2013-12-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| WO2013108754A1 (ja) | 2012-01-17 | 2013-07-25 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物 |
| CA2975072A1 (en) * | 2015-01-28 | 2016-08-04 | Astellas Pharma Inc. | Method for producing pyrazinecarboxamide compound and synthetic intermediate thereof |
| MA42623A (fr) | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| WO2018103663A1 (zh) * | 2016-12-09 | 2018-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 |
| EP3656769B1 (en) | 2017-07-19 | 2023-01-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor |
-
2021
- 2021-06-01 BR BR112022022220A patent/BR112022022220A2/pt unknown
- 2021-06-01 TW TW110119810A patent/TWI845843B/zh active
- 2021-06-01 JP JP2022574270A patent/JP7777544B2/ja active Active
- 2021-06-01 WO PCT/CN2021/097583 patent/WO2021244505A1/zh not_active Ceased
- 2021-06-01 MX MX2022013397A patent/MX2022013397A/es unknown
- 2021-06-01 EP EP21817710.3A patent/EP4159731A4/en active Pending
- 2021-06-01 US US17/917,435 patent/US12600714B2/en active Active
- 2021-06-01 CN CN202180039487.2A patent/CN115698000B/zh active Active
- 2021-06-01 CA CA3179395A patent/CA3179395A1/en active Pending
- 2021-06-01 KR KR1020227044988A patent/KR20230019444A/ko active Pending
- 2021-06-01 AU AU2021284676A patent/AU2021284676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115698000B (zh) | 2026-02-24 |
| CN115698000A (zh) | 2023-02-03 |
| JP2023528859A (ja) | 2023-07-06 |
| TW202146406A (zh) | 2021-12-16 |
| EP4159731A1 (en) | 2023-04-05 |
| AU2021284676A1 (en) | 2023-02-02 |
| KR20230019444A (ko) | 2023-02-08 |
| JP7777544B2 (ja) | 2025-11-28 |
| WO2021244505A1 (zh) | 2021-12-09 |
| US20230167099A1 (en) | 2023-06-01 |
| CA3179395A1 (en) | 2021-12-09 |
| EP4159731A4 (en) | 2024-06-26 |
| MX2022013397A (es) | 2022-12-13 |
| US12600714B2 (en) | 2026-04-14 |
| BR112022022220A2 (pt) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7773987B2 (ja) | スピロ環含有キナゾリン化合物 | |
| CN113767103B (zh) | 新型螺环类K-Ras G12C抑制剂 | |
| CN114901661B (zh) | 新型K-Ras G12C抑制剂 | |
| CN115315427B (zh) | Hpk1抑制剂及其制备方法和用途 | |
| JP2024514703A (ja) | ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 | |
| TW202306955A (zh) | 作為atr抑制劑的萘啶衍生物及其製備方法 | |
| TWI823255B (zh) | 作為Wee-1抑制劑的稠環化合物 | |
| WO2022012593A1 (zh) | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 | |
| CN116390728A (zh) | 喹唑啉衍生物及其制备方法和用途 | |
| US20250059206A1 (en) | Fused ring compound acting as shp2 inhibitor | |
| CN115867542B (zh) | 新型苯并咪唑化合物 | |
| CN115109061A (zh) | 三环化合物 | |
| US12600714B2 (en) | Substituted pyrazinecarboxamide compounds for treating diseases related to EGFR mutation | |
| JP2025507732A (ja) | Fak阻害剤としての化合物およびその使用 | |
| RU2857201C2 (ru) | Новое соединение пиразина | |
| JP2024547090A (ja) | Fak阻害剤としての化合物およびその使用 | |
| WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
| WO2022228512A1 (zh) | 作为Wee-1抑制剂的吡咯并嘧啶衍生物 | |
| WO2022171126A1 (zh) | 作为Wee-1抑制剂的稠环化合物 | |
| KR101418078B1 (ko) | mGluR5 길항제로서의 2-(치환된에티닐)퀴놀린 유도체 | |
| HK40084909A (en) | New pyrazine compound | |
| WO2022228511A1 (zh) | 作为Wee-1抑制剂的稠环化合物及其制备方法和用途 | |
| WO2022262857A1 (zh) | 芳基氧膦类化合物 | |
| CN117940430A (zh) | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 | |
| WO2023143344A1 (zh) | 新型egfr抑制剂 |